Elevated urine BMP phospholipids in LRRK2 and VPS35 mutation carriers with and without Parkinson’s disease

Sara Gomes, Alicia Garrido, Francesca Tonelli, Donina Obiang, Eduardo Tolosa, Maria José Martí, Javier Ruiz-Martínez, Ana Vinagre Aragón, Haizea Hernandez-Eguiazu, Ioana Croitoru, Vicky L. Marshall, Theresa Koenig, Christoph Hotzy, Frank Hsieh, Marianna Sakalosh, Elizabeth Tengstrand, Shalini Padmanabhan, Kalpana M. Merchant, Christof Bruecke, Walter PirkerAlexander Zimprich, Esther Sammler (Lead / Corresponding author)

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)
102 Downloads (Pure)

Abstract

Elevated urine bis(monoacylglycerol)phosphate (BMP) levels have been found in gain-of-kinase function LRRK2 G2019S mutation carriers. Here, we have expanded urine BMP analysis to other Parkinson’s disease (PD) associated mutations and found them to be consistently elevated in carriers of LRRK2 G2019S and R1441G/C as well as VPS35 D620N mutations. Urine BMP levels are promising biomarkers for patient stratification and potentially target engagement in clinical trials of emerging targeted PD therapies.
Original languageEnglish
Article number52
Number of pages4
JournalNPJ Parkinson's disease
Volume9
DOIs
Publication statusPublished - 4 Apr 2023

Keywords

  • Parkinson's disease
  • Translational research

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Cellular and Molecular Neuroscience

Fingerprint

Dive into the research topics of 'Elevated urine BMP phospholipids in LRRK2 and VPS35 mutation carriers with and without Parkinson’s disease'. Together they form a unique fingerprint.

Cite this